pertuzumab

pertuzumab is a recombinant humanized monoclonal antibody used in the treatment of breast cancer, specifically HER2-positive breast cancer, in combination with trastuzumab and docetaxel. It is marketed by Roche and was approved by the US Food and Drug Administration in 2012. Genentech, a subsidiary of Roche, developed pertuzumab in collaboration with University of California, Los Angeles and Dana-Farber Cancer Institute. The development of pertuzumab involved the work of several researchers, including Dennis Slamon and Ursula Sauder.

● Introduction

Pertuzumab is used to treat HER2-positive metastatic breast cancer, a type of cancer that affects women and is characterized by the overexpression of the HER2/neu protein. The treatment of HER2-positive breast cancer often involves a combination of therapies, including surgery, radiation therapy, and chemotherapy, as well as targeted therapies such as trastuzumab and lapatinib. Researchers at Stanford University and University of California, San Francisco have made significant contributions to the understanding of HER2-positive breast cancer and the development of targeted therapies. The use of pertuzumab in combination with other therapies has been studied in several clinical trials, including the CLEOPATRA trial and the APRICOT trial, which were conducted by Roche and Genentech.

● Mechanism_of_action

The mechanism of action of pertuzumab involves binding to the HER2 protein, which is overexpressed in HER2-positive breast cancer cells. This binding prevents the HER2 protein from interacting with other HER family members, such as HER1 and HER3, and inhibits the signaling pathways that promote cell growth and survival. Researchers at Harvard University and Massachusetts Institute of Technology have studied the signaling pathways involved in HER2-positive breast cancer and the mechanism of action of pertuzumab. The development of pertuzumab was influenced by the work of scientists at National Institutes of Health and European Organization for Research and Treatment of Cancer.

● Medical_uses

Pertuzumab is used in combination with trastuzumab and docetaxel to treat HER2-positive metastatic breast cancer. It is also used as a neoadjuvant therapy, in combination with trastuzumab and chemotherapy, to treat early-stage breast cancer. The use of pertuzumab in combination with other therapies has been studied in several clinical trials, including the CLEOPATRA trial and the APRICOT trial, which were conducted by Roche and Genentech. Researchers at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center have made significant contributions to the development of pertuzumab and its use in the treatment of HER2-positive breast cancer. The American Society of Clinical Oncology and European Society for Medical Oncology have published guidelines for the use of pertuzumab in the treatment of HER2-positive breast cancer.

● Side_effects

The side effects of pertuzumab are similar to those of other monoclonal antibodies and include infusion reactions, fatigue, and diarrhea. Pertuzumab can also cause cardiotoxicity, which is a concern in patients with pre-existing heart disease. Researchers at University of Oxford and University of Cambridge have studied the side effects of pertuzumab and the mechanisms by which they occur. The US Food and Drug Administration and European Medicines Agency have approved pertuzumab for use in combination with other therapies, and have established guidelines for monitoring and managing its side effects. The National Comprehensive Cancer Network and American Cancer Society provide information and resources for patients and healthcare providers on the use of pertuzumab and its side effects.

● History

The development of pertuzumab began in the 1990s, when researchers at Genentech and University of California, Los Angeles identified the HER2 protein as a potential target for cancer therapy. The first clinical trials of pertuzumab were conducted in the early 2000s, and the drug was approved by the US Food and Drug Administration in 2012. The approval of pertuzumab was based on the results of the CLEOPATRA trial, which demonstrated its efficacy in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. Researchers at Duke University and University of Chicago have made significant contributions to the development of pertuzumab and its use in the treatment of HER2-positive breast cancer. The European Organization for Research and Treatment of Cancer and American Association for Cancer Research have recognized the importance of pertuzumab in the treatment of HER2-positive breast cancer.

● Pharmacology

The pharmacology of pertuzumab involves its binding to the HER2 protein and inhibition of the signaling pathways that promote cell growth and survival. Pertuzumab is administered intravenously, and its pharmacokinetics have been studied in several clinical trials. Researchers at University of California, San Diego and University of Texas Southwestern Medical Center have studied the pharmacology of pertuzumab and its mechanisms of action. The US Food and Drug Administration and European Medicines Agency have established guidelines for the use of pertuzumab and its dosing and administration. The Pharmaceutical Research and Manufacturers of America and Biotechnology Innovation Organization have recognized the importance of pertuzumab in the treatment of HER2-positive breast cancer.

Category:Monoclonal antibodies